Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter’s Syndrome

INTRODUCTION: To improve outcomes of patients with Richter's syndrome (RS) and relapsed/refractory chronic lymphocytic leukemia (CLL), we modified the oxaliplatin and cytarabine doses of the oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR1) regimen for this phase I-II study (OFAR2). P...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tsimberidou, Apostolia M., Wierda, William G., Wen, Sijin, Plunkett, William, O’Brien, Susan, Kipps, Thomas J., Jones, Jeffrey A., Badoux, Xavier, Kantarjian, Hagop, Keating, Michael J.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4180513/
https://ncbi.nlm.nih.gov/pubmed/23810245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.012
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires